Biomea Fusion (BMEA) Q3 2026 earnings review
Biomea Fusion cuts trial costs, but its cash reserve shrinks
Biomea Fusion, a clinical-stage developer of diabetes and obesity pills, slowed its cash drain while reporting mixed early weight-loss data. Research spending dropped 41% from a year ago, which helped trim the quarterly cash drain to about $8 million by our math. Interim chief executive Mick Hitchcock highlighted a 6% weight drop in the Phase I trial of its obesity pill BMF-650, but that occurred in a confined clinic group whereas outpatients lost at most 3%.
| Cash and restricted cash | $26.8M down from $35.2M last quarter |
|---|---|
| Research and development spending | $8.5M -41% from a year ago |
| Operating loss | $13.0M down from $20.8M a year ago |
| COVALENT-211 readout plan | Unchanged 26-week data in Q1 2027 |
⚖️ Verdict: 🔴 Bearish
The story got worse because the company's obesity pill now faces a delay and its cash reserve is running tight. Management said BMF-650 needs longer animal safety studies and a licensing partner for late-stage development, while the $27 million cash balance leaves just over three quarters of funding by our math. On the positive side, completing enrollment in the first Phase II diabetes trial locks in a data readout for early 2027.
The question now is whether the diabetes drug icovamenib can deliver strong enough blood sugar reductions in early 2027 to attract new funding or a partner. Positive data would allow the company to refinance before cash runs out in mid-2027, whereas weak results would leave it short of funds before its second diabetes trial finishes. The 26-week COVALENT-211 readout in the first quarter of 2027 will decide.
🐂 Bull Case
Research Spending Cuts Slow the Cash Drain
Biomea Fusion, a clinical-stage developer of oral pills for diabetes and obesity, cut its operating expenses by 38% from a year ago to $13.0 million. After halting internal cancer drug work last year, the drugmaker lowered research and development spending by 41% to $8.5 million.
- Preclinical and exploratory programs: down $1.2 million from a year ago
- Manufacturing and external consultant costs: down $1.0 million each
- Research personnel costs: down $1.0 million after workforce reductions
- Quarterly cash drain: $8.4 million by our math, down from $11.1 million in the first quarter
This cost discipline matters because the company has no commercial products and funds its trials entirely from its cash balance. By shrinking its staff and facility footprint, management stretched its remaining funds into next year's clinical readouts.
What to watch: fourth-quarter cash usage in the annual report. A further drop would give management more breathing room as the first diabetes trial reads out in early 2027.
Diabetes Trials Reach Key Enrollment Milestones
Icovamenib is Biomea's experimental oral pill designed to restore insulin-producing cells in patients with diabetes. Interim chief executive Mick Hitchcock said the third quarter moved the drugmaker "closer to important Phase II data readouts for icovamenib in two distinct diabetes populations".
The company finished enrolling patients in COVALENT-211, its mid-stage trial for insulin-deficient type 2 diabetes, and dosed the first patient in OPAL, a British trial testing icovamenib alongside the obesity drug semaglutide. Completing enrollment locks in the 26-week follow-up clock, so the first efficacy data will arrive in the first quarter of 2027.
What to watch: completion of enrollment in the second diabetes trial, COVALENT-212. Finishing enrollment soon is necessary to keep that readout on track for the second quarter of 2027.
🐻 Bear Case
Outpatient Weight Loss Lagged Behind Confined Patients
BMF-650 is an experimental once-daily obesity pill that targets the GLP-1 hormone receptor to reduce appetite. Hitchcock said in the release that "BMF-650 achieved meaningful weight reduction while limited GI side effects were observed, all of which were Grade 1 AEs at the highest dose level".
However, the headline 6.1% weight loss at day 29 happened in Cohort 5, where volunteers stayed confined inside a clinic. In Cohorts 1 through 4, where outpatients lived at home, average weight loss ranged from 1.5% to 3.2% against 0.1% for placebo. Biomea noted that "As confinement appeared to affect eating behavior, these results should be interpreted separately from outpatient Cohorts 1-4".
In addition, the biotech said "additional clinical development of BMF-650 will require longer-term toxicology studies" and that it is "positioning the program for a potential strategic partnership, including licensing opportunities for late-stage development and commercialization". That means the drug will not enter mid-stage human testing without more animal safety work and an outside partner.
What to watch: whether a pharmaceutical partner licenses BMF-650 in 2027. Without a partner, Biomea lacks the capital to run large obesity trials on its own.
Cash Buffer Shrinks Ahead of 2027 Readouts
Biomea ended September with $26.8 million in cash, cash equivalents and restricted cash, down from $56.2 million at the end of 2025. Unlike in prior quarters, the press release did not state a specific quarter for how long its cash will last.
By our math, the third-quarter cash drain of $8.4 million leaves about 3.2 quarters of cash, which reaches into the second quarter of 2027. That timeline barely covers the COVALENT-211 readout in the first quarter of 2027 and the COVALENT-212 readout in the second quarter, while the OPAL obesity readout sits at the end of 2027.
What to watch: any licensing upfront payment or equity financing before mid-2027. Running low on cash during clinical readouts weakens management's hand in partnership talks.
Non-Cash Warrant Gain Halved the Reported Loss
Biomea reported a third-quarter net loss of $6.2 million, or $0.09 per share, down from a $16.4 million loss a year ago. However, the bottom line benefited from a $6.5 million accounting gain from the change in fair value of common warrant liabilities.
Warrant liabilities are accounting obligations tied to previously issued stock warrants, and their value fluctuates with the stock rather than business operations. Excluding that non-cash gain, the net loss was $12.7 million by our math, close to the $13.0 million loss from operations.
What to watch: loss from operations in the fourth quarter. That figure strips out warrant accounting swings and shows the true cost of running the clinical trials.
💲 Other KPIs
Working capital — short-term assets minus short-term bills — fell 43.2% from last quarter and 69.1% from the end of 2025. The drop has been steady across all three quarters this year as the drugmaker spends its cash reserves to fund ongoing diabetes and obesity trials.
Administrative and overhead spending rose 5.5% from a year ago and 22.3% from the second quarter. After falling in the first half of 2026 on staff cuts, spending turned upward this quarter because a $0.6 million rise in corporate expenses outweighed $0.4 million in payroll savings.
The share count rose 21.3% from a year ago following public stock offerings in late 2025, but grew only 0.3% from the second quarter. The higher share count spreads the net loss over more shares, which helped lower the reported loss per share from a year ago.
🔮 Guidance
Unchanged. The company still expects 26-week blood sugar reduction data for icovamenib in insulin-deficient type 2 diabetes in the first quarter of 2027. Earlier in the year, management had targeted the fourth quarter of 2026 before shifting the timeline by one quarter in the second-quarter report. Completing enrollment this quarter makes the current target achievable.
Unchanged. Biomea continues to expect 26-week data for icovamenib in patients whose blood sugar is not controlled on GLP-1 drugs in the second quarter of 2027. Like the sister trial, this schedule moved out from the fourth quarter of 2026 earlier this year. Patient enrollment remains ongoing.
New. Management gave its first readout target for the 24-week University of Leicester study testing icovamenib with semaglutide, setting topline data for the end of 2027 after dosing the first patient this quarter.
❓ Key Questions
Why did the release omit an explicit cash runway date?
In the second quarter, management projected its cash runway into the second quarter of 2027. This release stated only $26.8 million in cash without a runway date, leaving open whether upcoming toxicology studies or corporate costs altered the timeline.
What happened to the Type 1 diabetes academic trial?
Prior updates scheduled a Phase II trial in recently diagnosed Type 1 diabetes patients with four US academic centers to begin in the second half of 2026. The third-quarter highlights did not mention this study's status.
How long will the BMF-650 toxicology studies take?
Biomea said further clinical testing of BMF-650 requires longer-term animal toxicology studies. Management did not disclose the cost of these studies or when the drug will be ready to start a Phase II trial.
When will COVALENT-212 finish enrolling patients?
COVALENT-211 finished enrollment this quarter for a first-quarter 2027 readout, while COVALENT-212 is still enrolling for a second-quarter 2027 readout. To get 26-week data in the second quarter, enrollment must close before year-end.